Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Cisapride (R 51619): From Mechanistic Probe to Strategic ...

    2025-10-24

    Cisapride (R 51619): Strategic Foundations for Next-Generation Cardiac Electrophysiology and Translational Success

    Cardiac safety remains a critical bottleneck in drug development, with drug-induced arrhythmias accounting for a substantial proportion of late-stage failures and post-market withdrawals. The demand for predictive, mechanistically relevant tools is greater than ever, particularly as the industry pivots toward de-risking compounds earlier in the pipeline. Cisapride (R 51619), a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor, stands at the nexus of this challenge—uniquely positioned to empower translational researchers with both mechanistic precision and strategic flexibility.

    Biological Rationale: The Dual Mechanism—5-HT4 Agonism Meets hERG Inhibition

    At the molecular level, Cisapride is chemically defined as 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide, with a molecular weight of 465.95. Its nonselective activation of 5-HT4 receptors and potent inhibition of the human ether-à-go-go-related gene (hERG) potassium channel presents a dual-action platform for dissecting complex cardiac and gastrointestinal signaling pathways.

    • 5-HT4 receptor agonism modulates gastrointestinal motility and cardiac conduction, providing a window into serotonergic control of key physiological processes.
    • hERG channel inhibition is mechanistically linked to QT interval prolongation and increased arrhythmic risk, making Cisapride a reference compound for cardiac safety pharmacology studies.

    In the context of drug discovery, this duality is invaluable. Cisapride enables precise interrogation of 5-HT4-mediated signaling, while its robust hERG-blocking profile serves as a benchmark for arrhythmogenic potential—a central concern for translational researchers in both preclinical and clinical domains.

    Experimental Validation: Integrating Deep Learning, iPSC Models, and Cardiotoxicity Screening

    Traditional in vitro models—whether immortalized cell lines or animal-derived tissues—often fall short of recapitulating the nuanced electrophysiological landscape of the human heart. The emergence of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) has revolutionized the field, offering a scalable, human-relevant platform for phenotypic screening and mechanistic studies.

    Recent breakthroughs, such as the study by Grafton et al. (2021), have further elevated the predictive power of these models. Their research demonstrated that deep learning-based analysis of high-content images from iPSC-CMs can rapidly detect patterns of drug-induced cardiotoxicity, including those caused by ion channel blockers like Cisapride. The ability to screen a library of 1,280 bioactive compounds and identify those with cardiotoxic liabilities—using a single-parameter deep learning score—underscores a new era of high-throughput, target-agnostic toxicity assessment:

    "Compounds demonstrating cardiotoxicity in iPSC-CMs included DNA intercalators, ion channel blockers, epidermal growth factor receptor, cyclin-dependent kinase, and multi-kinase inhibitors... By using this screening approach during target discovery and lead optimization, we can de-risk early-stage drug discovery."
    — Grafton et al., eLife 2021

    For translational researchers, integrating Cisapride (R 51619) into such phenotypic screens offers a dual advantage:

    • Positive control for hERG-mediated cardiotoxicity, validating assay sensitivity and signal-to-noise ratio.
    • Tool for dissecting 5-HT4-driven responses, enabling mechanistic attribution in complex phenotypic outcomes.

    Furthermore, Cisapride’s high solubility in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), coupled with its solid-state stability at -20°C, ensures experimental reproducibility and robust storage logistics—critical for high-throughput workflows and longitudinal studies.

    Competitive Landscape: Elevating Cardiac Electrophysiology and Drug Safety Research

    The landscape of cardiac electrophysiology research is rapidly evolving. Compounds such as dofetilide, quinidine, and sotalol are commonly used reference hERG inhibitors, but they often lack the dual mechanistic footprint offered by Cisapride. As highlighted in recent thought-leadership discussions, Cisapride (R 51619) is uniquely positioned to reshape the contours of predictive cardiotoxicity research by:

    • Bridging cardiac safety pharmacology and gastrointestinal motility studies through its 5-HT4 and hERG duality.
    • Enabling direct comparison between distinct signaling pathways implicated in both therapeutic efficacy and off-target liabilities.
    • Facilitating de-risking strategies during early-stage compound triage and target validation.

    Existing product pages often focus on basic physicochemical properties and standard applications. This article, however, expands the narrative—integrating mechanistic insight, experimental best practices, and strategic guidance. We also synthesize lessons from advanced screening paradigms, such as deep learning-enabled phenotypic analysis, to provide a future-oriented perspective that transcends conventional product-centric content. For a comparison of prior thematic discussions, see "Redefining Cardiac Electrophysiology Research". Here, we escalate the conversation by placing Cisapride at the heart of translational strategy, not merely as a tool, but as a catalyst for innovation in model systems and screening methodologies.

    Clinical and Translational Relevance: De-risking Early Drug Development

    Late-stage drug attrition due to unanticipated cardiotoxicity incurs not only massive financial costs but also delays in therapeutic innovation. As underscored by Grafton et al., cardiotoxicity accounts for approximately one-third of all drugs withdrawn due to safety concerns. The integration of human-relevant, scalable in vitro platforms—powered by iPSC-derived cardiomyocytes and next-generation analytics—now makes it possible to interrogate cardiac safety at unprecedented depth and throughput.

    Cisapride (R 51619) serves as a linchpin in these workflows, enabling translational researchers to:

    • Calibrate and validate cardiac safety assays with a compound whose mechanistic liabilities are well-documented.
    • Benchmark novel compounds against a gold-standard hERG inhibitor and 5-HT4 agonist, ensuring comprehensive risk assessment.
    • Support regulatory submissions with robust, reproducible datasets that mirror clinical scenarios of arrhythmogenic risk.

    By deploying Cisapride in conjunction with advanced models and screening technologies, translational teams can proactively identify and mitigate safety liabilities—transforming risk management from a retrospective exercise into an integral part of discovery and development. This strategy is not only scientifically rigorous but also operationally efficient, potentially reducing time-to-clinic and overall R&D expenditure.

    Visionary Outlook: Toward Integrated, Predictive, and Human-Relevant Cardiac Safety Paradigms

    The future of cardiac electrophysiology and drug safety research lies at the intersection of mechanistic insight, high-content phenotypic screening, and strategic translational planning. As the field moves toward integrated platforms that combine iPSC technology, deep learning, and multiparametric readouts, the demand for well-characterized, dual-mechanism probes like Cisapride (R 51619) will only intensify.

    Looking ahead, we envision:

    • Expanded application of Cisapride in systems biology and network pharmacology studies, elucidating crosstalk between serotonergic and electrophysiological pathways.
    • Integration with patient-derived iPSC models to personalize safety screens and de-risk precision therapeutics.
    • Synergy with automated, AI-driven image analysis to accelerate discovery timelines and enhance predictive fidelity.

    For researchers committed to advancing the frontier of translational science, Cisapride (R 51619) is more than a product—it is a strategic enabler, uniquely suited for the demands of next-generation cardiac safety and mechanistic research. Its high purity (99.70%), comprehensive quality control (HPLC, NMR, MSDS), and proven utility in both cardiac and gastrointestinal domains cement its role as an indispensable asset in the translational toolkit.

    Conclusion: Escalating the Dialogue—From Product Utility to Strategic Vision

    While most product pages and technical briefs dwell on basic features, this article has sought to escalate the dialogue—placing Cisapride (R 51619) at the center of an evolving translational research paradigm. By weaving together mechanistic detail, experimental validation, strategic analysis, and a visionary outlook, we offer a roadmap for researchers seeking to harness the full potential of this dual-mechanism compound.

    For those ready to unlock deeper insights into cardiac electrophysiology, de-risk early drug development, and set new standards in translational science, Cisapride (R 51619) stands ready as your precision tool and strategic catalyst.